TY - JOUR
KW - anticoagulation
KW - Atrial fibrillation
KW - non-vitamin K antagonist oral anticoagulants
KW - off-label dose reduction
AU - C. van den Dries
AU - R. Pajouheshnia
AU - H. van den Ham
AU - P. Souverein
AU - K. Moons
AU - A. Hoes
AU - G. Geersing
AU - S. van Doorn
AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
AN - 36102068
BT - Br J Clin Pharmacol
DO - 10.1111/bcp.15534
DP - NLM
ET - 2022/09/15
LA - eng
N1 - 1365-2125
van den Dries, Carline J
Pajouheshnia, Romin
Orcid: 0000-0002-4208-3583
van den Ham, Hendrika A
Souverein, Patrick
Orcid: 0000-0002-7452-0477
Moons, Karel G M
Hoes, Arno W
Geersing, Geert-Jan
van Doorn, Sander
Journal Article
England
Br J Clin Pharmacol. 2022 Sep 14. doi: 10.1111/bcp.15534.
PY - 2022
SN - 0306-5251
T2 - Br J Clin Pharmacol
TI - Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
ER -